Bioprocessing & Manufacturing



With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale. Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.




Bioprocess & Manufacture, Wednesday 4 April 2018

Bioprocess & Manufacture

Chair’s opening remarks

Vaccine Bioprocessing

Dr Don Gerson
Bioprocess & Manufacture

What can we learn from mAB bioprocessing to vaccines to make more vaccines? From R&D to full scale manufacturing and worldwide distribution

  • The transition from lab to manufacturing and large-scale production of low cost vaccines globally
Parrish Galliher
Bioprocess & Manufacture

Practical solutions enabling rapid production of viral based therapies

Dr Ahd Hamidi
Bioprocess & Manufacture

Latest advancements in production process intensification to support demand for affordable vaccines

  • Use of fixed-bed bioreactors
  • Development of microfacilities
Bioprocess & Manufacture

Overview of cell culture & new expression systems improving vaccine bioprocessing


Networking coffee break

Dr Hari Pujar
Bioprocess & Manufacture

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

Bioprocess & Manufacture

New VLP production techniques: Challenges and opportunities

Vaccine Production and Delivery Systems

Dr Max Søgaard
Bioprocess & Manufacture

ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

Wendy Saffell-Clemmer
Bioprocess & Manufacture

Analytical characterization of aluminum adsorbed vaccines: Stability indicating methods for product release

  • What general guidance is there on release and stability test methods for aluminum adsorbed vaccines?  
  • Understanding of the antigen stability following adsorption
  • Reviewing potential release tests and proposing a panel of stability indicating tests for aluminum adsorbed vaccines

Networking Lunch & Poster Session

Darin Zehrung
Bioprocess & Manufacture

Review of the current alternative vaccine delivery methods and how their effectiveness is assessed

  • The advantages and progression of up taking alternative delivery systems and packaging
  • The logistical challenges to consider for developing countries
  • How to make new technologies applicable and build a stronger business case to be used
  • Total system effectiveness: Cost modelling of delivery systems
Michael A. Schrader
Bioprocess & Manufacture

Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

  • Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity
  • Logistical conquest in easy administration, shelf life stability and only minutes of wear time
  • Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake
Dr Gregory Glenn
Bioprocess & Manufacture

Solutions for intradermal administration & clinical experience with the MicronJet600R

Bioprocess & Manufacture

Accelerating vaccine development & biomanufacturing using a universal, non-viral delivery platform for engineering of relevant cell types

  • Rapidly express mg to gram quantities of MAbs, recombinant proteins, viral vectors, and VLPs
  • Bench to bedside scalability in cells relevant to bioproduction (CHO, HEK, Vero, MDCK, BHK21, insect cells, etc.)
  • Synergize and streamline migration from transient expression to stable cell line generation
Senior representative, Maxcyte

Networking coffee break

Bioreactor needs for the developed & developing world

Peter Khoury
Bioprocess & Manufacture

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

  • Understanding in securing strains, safety,  regulatory hurdles and manufacturing hurdles
  • Considering the logistics of distribution
Bioprocess & Manufacture

A platform approach for viral vaccine manufacturing

  • Our platform approach for the manufacturing of viral vaccines
  • How technological developments help to set-up a robust and scalable process using single use technologies
Reserved for Millipore Sigma
Dr Yan-ping Yang
Bioprocess & Manufacture

Continuous Process for Vaccine Manufacturing: Challenges and opportunities

  • Experiences & lessons learned from the industry on continuous processing
  • Disposable technology & continuous technology: a powerful combination
  • Rapid technology advancement for key enablers to support continuous processing
  • FDA Fully on Board with the Concept of continuous processing

Chair’s closing remarks and close of congress day 2


Networking Drinks & Party

last published: 18/Jan/18 11:05

Bioprocess & Manufacture, Thursday 5 April 2018

Enabling Technologies from Discovery to Market

Prof Fikri Avci
Bioprocess & Manufacture

Understanding how vaccines elicit immune responses

Dr Frederick Porter
Bioprocess & Manufacture

Enabling translation of vaccine discovery into clinical candidates in academia

Dr Fiona Lin
Bioprocess & Manufacture

Designing vaccines focusing on critical quality attributes and analytical strategies


Networking coffee break

Dr Viliam Pavliak
Bioprocess & Manufacture

Developing vaccines for developing countries – A case study on Typhoid conjugate vaccine


Networking Lunch & Poster Session


last published: 18/Jan/18 11:05



Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit


Marc Rhys-Evans
+44 20 7827 5945




To Register


Tayyab Abbasi
+44 20 7092 1210




Press Relations


Karina Kusova
+44 20 7092 1071